Clinical Trials Browser

Phase 1/2 × INDUSTRY × Ado-Trastuzumab Emtansine × Clear all

NCT06324357 2026-03-18

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Phase 1/2 Recruiting

BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

NCT05593094 2026-02-25

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

Phase 1/2 Active not recruiting

Brain Neoplasms

NCT05081609 2026-02-24

IL Believe

Phase 1/2 Active not recruiting

Uterine Cervical Neoplasms, Neoplasm Metastasis

NCT04298918 2021-11-08

A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Phase 1/2 Terminated

Breast Neoplasms

NCT00934856 2017-04-06

A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer

Phase 1/2 Completed

98 enrolled 40 charts

Breast Neoplasms

NCT00951665 2016-06-24

A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer

Phase 1/2 Completed

107 enrolled 31 charts

Breast Neoplasms

NCT00875979 2013-12-24

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

Phase 1/2 Completed

67 enrolled 9 charts

Breast Neoplasms